EU Clinical Trial 2018-001284-24

A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma  May 22, 2019

Main objective of the trial: To evaluate the efficacy of zanubrutinib in relapsed or refractory marginal zone lymphoma as measured by overall response rate in accordance with the Lugano Classification determined by independent central review

Parties

Sponsors
Countries
AU CN FR GB IT NZ US
Keywords
BGB-3111 Marginal zone lymphoma Zanubrutinib

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.